Journal of Diabetology

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Reach Us +1 (629)348-3199

Editorial - Journal of Diabetology (2025) Volume 9, Issue 1

Beyond Blood Sugar: Cardiovascular and Weight Loss Benefits of GLP-1 Agonists

Eliza straw*

School of Health, Medical and Applied Sciences, Central Queensland University, Sydney, Australia

*Corresponding Author:
Eliza straw
School of Health, Medical and Applied Sciences
Central Queensland University, Sydney, Australia
E-mail: elzastw@cqumail.com

Received: 01-Mar-2025, Manuscript No. AADY-25-166638; Editor assigned: 03-Mar-2025, PreQC No. AADY-25-166638(PQ); Reviewed: 16-Mar-2025, QC No. AADY-25-166638; Revised: 22-Mar-2025, Manuscript No. AADY-25-166638(R); Published: 25-Mar-2024,DOI:10.35841/aady-9.1.247

Citation: straw E. Beyond blood sugar: Cardiovascular and weight loss benefits of GLP-1 agonists. J Diabetol. 2025;9(1):247

Visit for more related articles at Journal of Diabetology

Introduction

Glucagon-like peptide-1 (GLP-1) agonists have revolutionized the management of type 2 diabetes mellitus (T2DM) by effectively controlling blood glucose levels. However, recent research has highlighted benefits that extend well beyond glycemic control. These include significant positive impacts on cardiovascular health and weight management. This mini-article explores the expanding role of GLP-1 agonists, emphasizing their cardiovascular protective effects and weight loss benefits, which have made them valuable tools in modern medicine.

GLP-1 is an incretin hormone secreted by the gut in response to food intake. It stimulates insulin secretion, inhibits glucagon release, delays gastric emptying, and promotes satiety. GLP-1 receptor agonists (GLP-1 RAs) are synthetic analogs that mimic the action of natural GLP-1 but have longer half-lives, enabling effective therapeutic use. Commonly prescribed GLP-1 RAs include liraglutide, semaglutide, dulaglutide, and exenatide.

Initially developed to improve glycemic control, these drugs enhance insulin secretion in a glucose-dependent manner, reducing the risk of hypoglycemia. Beyond this, clinical trials and observational studies have identified their ability to reduce cardiovascular events and aid in sustained weight loss, which are critical concerns in patients with diabetes.

Cardiovascular disease (CVD) remains the leading cause of morbidity and mortality among patients with T2DM. The link between diabetes and increased cardiovascular risk is well-established, necessitating therapies that address both blood sugar and cardiovascular health.

These effects collectively reduce the risk of heart attacks, strokes, and heart failure, making GLP-1 agonists a vital component of comprehensive diabetes care with cardiovascular benefits.

Weight Loss Effects and Mechanisms

Obesity is a major driver of insulin resistance and T2DM, and weight loss is crucial in managing these conditions. GLP-1 agonists have demonstrated consistent weight reduction in patients, often leading to improvements in metabolic health.

Clinical studies report an average weight loss of 5-10% of body weight over months, which is substantial and clinically meaningful. For example, the STEP trials focusing on semaglutide for obesity management (including non-diabetic individuals) showed remarkable weight loss, with some participants losing over 15% of their body weight.

Importantly, weight loss achieved with GLP-1 RAs contributes to better glycemic control, improved blood pressure, and reduced cardiovascular risk—creating a positive health feedback loop.

Expanded Therapeutic Uses

Given their dual benefits on cardiovascular outcomes and weight, GLP-1 agonists have gained FDA approval not only for T2DM but also for chronic weight management in obesity (e.g., liraglutide as Saxenda, semaglutide as Wegovy).

Safety and Considerations

GLP-1 agonists are generally well tolerated. The most common side effects are gastrointestinal, including nausea, vomiting, and diarrhea, which often improve over time. Rare but serious risks include pancreatitis and potential thyroid C-cell tumors, though these remain under ongoing evaluation.

They are injectable medications, typically administered once daily or weekly, which may affect patient adherence but advances in delivery devices have improved convenience. [9, 10].

Conclusion

GLP-1 receptor agonists have emerged as a cornerstone therapy for type 2 diabetes, with benefits that transcend blood sugar control. Their proven cardiovascular protection and potent weight loss effects address two major health challenges in diabetic and obese populations. The growing evidence supporting their use in broader metabolic conditions highlights their importance in holistic patient care. As ongoing research continues to unfold, GLP-1 agonists are poised to remain essential agents in managing cardiometabolic health beyond glycemia alone.

References

  1. Sica D, Carl D. Pathologic basis and treatment considerations in chronic kidney disease-related hypertension. Semin Nephrol. 2005 (Vol. 25, No. 4, pp. 246-251).

    2. Indexed at, Google Scholar, Crossref

  2. Coresh J, Selvin E, Stevens LA, et al. Prevalence of chronic kidney disease in the United States. Jama. 2007;298(17):2038-47.

    3. Indexed at, Google Scholar, Crossref

  3. Vasavada N, Agarwal R. Role of excess volume in the pathophysiology of hypertension in chronic kidney disease. Kidney Int. 2003;64(5):1772-9.

    4. Indexed at, Google Scholar, Crossref

  4. Sato A, Hayashi K, Saruta T. Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease. Am J Hypertens. 2005;18(1):44-9.

    5. Indexed at, Google Scholar, Crossref

  5. Larivière R, Lebel M. Endothelin-1 in chronic renal failure and hypertension. Can J Physiol Pharmacol. 2003;81(6):607-21.
    6. Indexed at, Google Scholar, Crossref
Get the App